Smigelski is a chief resident at NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York.
Management of hormone-naïve oligometastatic prostate cancer
Growing evidence supports the existence of an intermediate metastatic disease state.
Experts urge FDA to remove black box warning on low-dose vaginal estrogen
Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published in The Lancet
Urology in focus: Key moments from 2025
Enrollment goal met in trial of 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11 PET/CT